Serum CD26 Levels and Colorectal Cancer
Author Information
Author(s): Cordero O J, Ayude D, Nogueira M, Rodriguez-Berrocal F J, Cadena M Paez de la
Primary Institution: Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Santiago de Compostela
Hypothesis
The study examines the diagnostic and prognostic value of preoperative serum CD26 measurements in colorectal carcinoma patients.
Conclusion
Preoperative serum CD26 levels can effectively differentiate between healthy individuals and colorectal cancer patients, showing high sensitivity and specificity.
Supporting Evidence
- Healthy donors had a mean sCD26 level of 559.7 μg l–1, while cancer patients had a mean of 261.7 μg l–1.
- A cut-off at 410 μg l–1 provided 90% sensitivity and specificity for diagnosing colorectal cancer.
- The diagnostic efficiency of sCD26 is higher than that of other markers, especially in early-stage patients.
Takeaway
Doctors can use a blood test to check for a substance called CD26 to help find out if someone has colorectal cancer.
Methodology
The study used ELISA to measure serum CD26 levels in colorectal carcinoma patients and healthy donors.
Statistical Information
P-Value
< 0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website